Navigation Links
EURO in Medical Technology

First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008

PARIS, March 24 /PRNewswire-FirstCall/ -- The AXA Research Fund closed out its first year of existence. During the year ended, the Fund granted more than Euro 13 million to various European research institutions. The purpose of the Fund is to promote the understanding and prevention of major ...

Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease

EINDHOVEN, the Netherlands, April 1 /PRNewswire/ -- The Center for Translational Molecular Medicine (CTMM) - a Dutch public-private partnership committed to the research and development of new techniques for the diagnosis and treatment of major diseases - announced today that nine projects wil...

CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research

...olecular Medicine) today announced the successful completion of 265 million euro funding for translational (bench-to-bedside) medical research, making CTMM ... destinations for translational biomedical research. "The 15 million euro allocated to this prostate cancer project, which brings the total allocated...

CoAxia, Inc. Announces $21.5M Series D Financing

...iences sectors. Since 1972, the firm has financed over 450 companies, many of which have gone public or have been acquired, and currently manages over euro 1 billion in assets. Sofinnova's experienced team and hands-on approach in nurturing and supporting portfolio companies from initial financing to succ...

Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting

...ranostics.com . (1) N. Pavlidis, E. Briasoulis, J. Hainsworth, F.A. Greco. Diagnostic and therapeutic management of cancer of an unknown primary. euro J of Cancer. 2003; 39:1990-2005. (2) D. V. Schapira and A. R. Jarrett. The need to consider survival, outcome, and expense when evaluating and tr...

Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults

... fields of central nervous system and immunology disorders. Employing approx. 10 000 people in over 40 countries, UCB achieved revenues of 3.6 billion euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB). Forward looking statement This press release contains forward-looking statemen...

Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis

...d commercialization of drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Founded in May 2005, Fovea has raised euro 50.5m ($69m) in two financing rounds from a strong international syndicate of investors. Fovea has built a project portfolio including internal r...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

...first clinical trial application (CTA) in Europe by its partner Nycomed for the anti-GM-CSF antibody MT203. Micromet received a payment of 1.5 million euro (US$ 2.0 million) from Nycomed for the achievement of this milestone. Under a 2007 agreement between the two companies, Micromet and Nycomed are ...

Drug Development Program Started Based on CAP(R) Human Cell Line

...rlands), CEVEC Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The Netherlands) announce the start of Theraptech, a 2.4 million euro therapeutic protein development program subsidized under the European Trans Bio Program. The major objective of the Theraptech project is to develop a...

Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance

...available in all markets. With an annual R&D expenditure of around euro 1bn, Merck Serono is committed to growing its business in specialist-focuse...erck is a global pharmaceutical and chemical company with total revenues of euro 7.6 billion in 2008, a history that began in 1668, and a future shaped by 3...

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

... for 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2007, revenues reached euro 1.063 billion with 84% of sales outside of France. bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine ...

New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures

... central nervous system and immunology disorders. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on NYSE Euronext (symbol: UCB). Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta...

Cambridge Laboratories Announces Approval of Tetrabenazine in Spain

...he fields of central nervous system and immunology disorders. Employing around 12 000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB). For further details: Cambridge Laboratories Mark Evans, CEO +44-191-296-93...

Siemens Introduces New Standard of Care for Breast Ultrasound

...8 (Sept. 30), Siemens Healthcare reported sales of euro 11.2 billion, orders of euro 11.8 billion, and Sector profit of euro 1.2 billion. Further information can be found by v...

Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation

..., Fidan D, Maggioni AP, Lopez-Sendon J, Stepinska J, Cokkinos DV, Crijns HJ. Costs of atrial fibrillation in five European countries: Results from the euro Heart Survey on atrial fibrillation. Europace. 2008 Apr;10(4):403-11. Epub 2008 Mar 7. (5) Wattigney WA, circulation. 2003;108:711-716. (6) Fuster...

Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus

... central nervous system and immunology disorders. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on NYSE Euronext (symbol: UCB). Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta...

CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years

...he fields of central nervous system and immunology disorders. Employing around 12 000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB). UCB's North American headquarters is located in Atlanta, Ga. Forward-looking statement ...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

...he fields of central nervous system and immunology disorders. Employing around 12 000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB). Forward-Looking Statement This press release contains forward-looking statements based ...

CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients

...he fields of central nervous system and immunology disorders. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB). Forward-Looking Statement This press release contains forward-looking statements based ...

European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder

...d marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please ...

Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials

... expenditure was about euro 185 million, in excess of 20% of consolidated sales, which amounted to euro 920.5 million while total revenues amounted to euro 993.8 million. Ipsen's shares are traded on Segment A of Eurolist by Euronext(TM) (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligi...

NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.

...development of these compounds going forward. To date, NicOx has received euro 19.2 million from Merck under this agreement. NicOx also stands to receive potential additional milestone payments of euro 269 million and industry standard royalties on the sales of products which ...

Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests

...7 (Sept. 30), Siemens Healthcare reported sales of euro 9.85 billion (on a pro forma basis including Dade Behring roughly euro 11 billion), orders of euro 10.27 billion, and group profit of...

New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain

..., immune and inflammatory disorders and oncology. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atla...

BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University

...lobal challenges such as climate protection, energy efficiency, nutrition and mobility. BASF has more than 95,000 employees and posted sales of almost euro 58 billion in 2007. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information on BASF is ava...

Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy

..., immune and inflammatory disorders and oncology. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atla...

Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain

..., immune and inflammatory disorders and oncology. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atla...

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

...uring 2007 reaching euro 20.6 million, compared to euro 9.6 million in 2006. This increase is primarily du...., Inc. and Pfizer Inc. Operating expenses totaled euro 57.8 million in 2007, compared to euro 36.3 million in 2006. The majority of these expens...

Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing

...7 (Sept. 30), Siemens Healthcare reported sales of euro 9.85 billion (on a pro forma basis including Dade Behring roughly euro 11 billion), orders of euro 10.27 billion, and group profit of...

FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria

... securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. About sanofi-aventis Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes th...

Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System

.... 30), Siemens Medical Solutions reported sales of euro 9.85 billion, orders of euro 10.27 billion, and group profit of euro 1.32 billion (preliminary figures, unaudited). Fur...

Keppra XR(TM) Extended-Release Tablets Filed with the FDA

... securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and through its affiliate. SCHWARZ PHARMA AG (Monheim, Germany) is ...

Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu

.... 30), Siemens Medical Solutions reported sales of euro 9.85 billion, orders of euro 10.27 billion, and group profit of euro 1.32 billion (preliminary figures, unaudited). Fur...

UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets

... securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and through its affiliate, owns approx. 89% of the shares of SCHWAR...

Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio

...30th), Siemens Medical Solutions reported sales of euro 9,85 billion, orders of euro 10,27 billion, and group profit of euro 1,32 billion (preliminary figures, unaudited). Fur...

NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020

...l manage and fund development activities through to product registration and NicOx stands to receive an undisclosed share of future revenues and up to euro 52.9 million in potential milestones and commercial success fees. Study design and endpoints The trial is a 6-week, multi-center, double blind, plac...

CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year

... securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approx. 88% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA ...

Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome

... securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approximately 88% of the shares of SCHWARZ PHARMA AG. SCHWARZ P...

Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease

... securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange and owns approximately 88% of the shares of SCHWARZ PHARMA AG. SCHWARZ P...

In New Study, Duloxetine Reduced Non-specific Pain and Emotional Symptoms Associated with Depression

...nd marketing novel products of high therapeutic value for human and veterinary medicine. In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development. Duloxetine for majo...
Other Tags
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the addition of the "The Global ... their offering. ... an overview of the global digital media ... control and monitor piracy by securely and ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
(Date:12/26/2014)... The Biofeedback Federation of Europe annual meeting ... Rome, Italy and is hosted by the Salesian Pontifical ... a wide variety of topics such as ADHD, anxiety, ... in athletes. The scientific program will feature the latest ... allows clients to see what is going on in ...
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
Other Contents